Imagine reversing that very first oncogenic mutation. Now press play. Will it always grow the same tumor?
Cancer genetics has assumed yes—or close enough—for decades. After sequencing millions of tumors, researchers found that KRAS, BRAF, EGFR, and HRAS repeatedly rear their heads. Precision oncology matches tumors to targeted therapies based on the idea that driver mutations determine their fate.
However, cancer rarely repeats itself. Two patients with the same driver mutation can have very different diseases. Their tumors develop differently, progress faster, and respond differently to identical treatments. “We all have different inherited genes, and we all live different lives. We’re exposed to different things,” Sarah J. Aitken, PhD, first author of the study and an assistant professor of pathology and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, told Inside Precision Medicine. “That becomes very complicated to disentangle—what’s causing what and why different patients might respond to different things in different ways even though they seem to have the same disease.”
Researchers have blamed environmental exposures, additional mutations, and simple bad luck. But a study published in Nature argues that another determinant has been hiding in plain sight all along: the inherited genome in which those mutations arise. Rather than acting independently, cancer-driving mutations may interact extensively with an individual’s genetic background, fundamentally altering how tumors evolve from their earliest beginnings. The implications go beyond mouse genetics. The same mutation—which clinicians may use to guide treatment—may have different biological effects in different people. Instead, its effects depend on the surrounding inherited genetic landscape.
“One of the goals in diagnostics and precision medicine is to identify the genetic change, driver mutation, or specific marker in this particular cancer that will work and cure the patients—it does in some people, but not in many others,” said Aitken. “Even if what we’re trying to do is identify this magic target to treat, if the combination of genetic backgrounds is going to make someone’s driver behave differently in different people, it doesn’t tell us what we do need to do, but it maybe tells us why different people respond in different ways. So… maybe we need to be looking at this particular driver in this genetic background, not just the specific driver itself.”
Earliest cancer moments, rewound
Most cancer research begins at the end of the story. Before being diagnosed, a tumor has evolved for years or decades. Sequencing data can help scientists reconstruct that history, but they cannot directly observe how the first mutated cells competed, survived, or disappeared. Human studies are complicated because each patient has unique genetics, environmental exposures, lifestyle, diet, and chance.
Aitken and colleagues wanted to eliminate most of those variables. So, they did something humans cannot do to untangle those variables: they repeated cancer evolution hundreds of times.
In a classic chemically induced liver cancer model, they gave four genetically distinct mouse strains a single dose of the DNA-damaging carcinogen diethylnitrosamine (DEN) at the same developmental stage. All mice were exposed under the same lab conditions. The tumors were analyzed using whole-genome sequencing, transcriptomics, and histopathology.
The design allowed one variable to dominate: inherited genetics. “The idea was that we could remove a lot of that heterogeneity that exists in human populations,” Aitken explained. “We can remove all the different variables except inherited genetics, so we know exactly what we’ve exposed them to. We give them one dose of a single drug at the same time. Everything else is the same. Then, any differences we see, we think we can ascribe to those inherited differences.”
The design resembles evolutionary biologist Stephen Jay Gould’s famous thought experiment from his 1989 book Wonderful Life of “replaying the tape of life,” asking whether evolution would unfold the same way if history could begin again. Here, instead of replaying the evolution of life, the researchers replayed the evolution of cancer hundreds of times under nearly identical conditions.
Identical mutations, different biology
The researchers started with simple expectations. One genetic background may have produced tumors faster than another due to more mutations. However, the data indicated otherwise. “We had preconceptions,” Martin S. Taylor, PhD, co-senior author from the Medical Research Council Human Genetics Unit at the University of Edinburgh, told Inside Precision Medicine. “They proved to be wrong, as is often the case. But you do the experiment.”
The researchers found that the most cancer-prone mouse strain often needed fewer genetic changes to become cancerous. More resistant strains mutated but developed tumors slower. This changed the study’s focus from mutagenesis to evolution. “It wasn’t that mutation load was driving things,” Taylor said. “It was differences in selection.”
It seems subtle, but it changes how researchers view early tumor development. Mutations are constant, and most disappear without consequence. Mutated cells that survive, grow, and become cancerous are selected. Even more surprising, identical driver mutations rewired downstream biology differently depending on the inherited genome.
Aitken pointed to the tumor suppressor p53 as an example. “In some of the strains, when you mutate one particular driver, it makes p53 signaling go up. In other strains, exactly the same driver—exactly the same thing that we’re trying to diagnose—makes p53 go in the opposite direction.”
That observation is striking because driver mutations were once considered discrete molecular events with predictable downstream effects. In this case, the inherited genome changed how mutations spread through signaling networks.
The study found significant interactions between p53 signaling, TGFβ, and PPAR pathways, which regulate cell growth, differentiation, metabolism, inflammation, and programmed cell death. Most importantly, all strains activated the core MAPK pathway. The broader cellular response to activation changed.
When they studied early tumor formation, researchers found another surprise. Conventional thinking holds that cancer develops gradually through mutations until a cell becomes malignant. However, using lesion segregation, which Taylor’s group discovered several years earlier, the researchers were able to reconstruct the first generations of cells after DNA damage.
Several tumors appeared immediately. Others took several rounds of cellular evolution to clone. The most susceptible mouse strain, C3H, often transformed after one major driver mutation. More resistant strains had two or more driver events before tumors formed. Many early cellular lineages disappeared before contributing to cancer, even with similar mutations.
Those findings suggest a major perspective shift. Researchers may need to ask why certain inherited genomes help mutated cells survive the early rounds of evolutionary competition rather than why some people have more mutations. “We were initially expecting that perhaps we’d see more mutations in the mice that developed tumors more quickly,” Taylor said. “Actually, we saw sort of the opposite.” Selection, not mutation, emerged as the dominant force.
Ordinary genetic variation, extraordinary effects
A part of the study that surprised the researchers was that the study mice were not engineered to carry high-risk cancer mutations. They were not inherited cancer models. Instead, they represented natural genetic diversity.
“These are basically wild-type mice,” Taylor said. “They haven’t got strong predisposition effects. They’ve naturally accumulated variation, which is probably more reflective of what’s happening in the human population than genetically modified mouse models.” That observation broadens the significance of the findings.
Most inherited cancer research has focused on rare, high-penetrance mutations like BRCA1, BRCA2, or TP53 that greatly increase cancer risk. Mutations account for a small percentage of cancers. Most are caused by thousands or millions of relatively common variants that have little effect on disease risk. This Nature study suggests that ordinary differences may collectively influence tumor evolution more than previously thought.
Aitken and Taylor avoid exaggerating. The controlled chemically induced liver cancer model was used in mice only. Human cancers develop over decades due to environmental exposures, aging, inflammation, and other biological factors.
Thus, this study’s driver mutations cannot predict human cancers. The work’s significance is its principle. Eliminating nearly every confounding variable except inherited genetics showed that germline variation can influence nearly every stage of tumor evolution, from the number of mutations needed for transformation to which oncogenic drivers succeed, how they interact with cellular signaling pathways, and how quickly cancers emerge.
Human population observations support the findings. Previous genomic studies have found differences in driver mutation frequency among ancestry groups that are difficult to explain by environmental exposure or mutational processes.
Taylor believes the study offers one plausible biological mechanism. “We know that you get differences in driver frequencies across different population groups,” he said. “We don’t really have a very good handle on why that’s the case.” The interactions observed between inherited genetic background and driver mutations, he argues, may represent part of that explanation.
Putting the precision in “precision oncology”
The implications of this paper could be paradigm shifting for precision oncology, which has transformed cancer care by reading the genomes of tumors. This study suggests the next frontier may involve reading two genomes simultaneously. One belongs to the cancer. The other belonged to the patient long before the first cancer cell appeared. Together, they may determine far more than researchers once imagined.
But there’s still a long way to go in this tale before we can change people’s lives for the better. “It doesn’t tell us what we need to do,” Aitken said. “But maybe it tells us why different people respond in different ways. Maybe we need to be looking at this particular driver in this genetic background—not just the specific driver itself.”
Cancer is often described as evolution unfolding inside the body. But evolution never begins with a blank slate. Every driver mutation emerges within an inherited genome shaped over millions of years of evolutionary history—a genome that may influence which mutations survive, which biological pathways they perturb, and ultimately whether a damaged cell ever becomes a tumor. The mutation may ignite the process. This study suggests the inherited genome helps decide how the fire spreads.
The post Cancer’s Hidden Axis: Genetic Background Drives Tumor Evolution appeared first on Inside Precision Medicine.